New hope for advanced kidney cancer: first human trial of NEO-811 begins

NCT ID NCT07300241

First seen Jan 11, 2026 · Last updated May 11, 2026 · Updated 18 times

Summary

This early-stage study tests a new drug called NEO-811 in people with advanced clear cell kidney cancer that cannot be removed by surgery. About 30 participants who have tried other treatments or cannot take them will receive the drug to see if it is safe and what dose works best. The goal is to control the disease, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NEO-811 Dallas Site

    RECRUITING

    Dallas, Texas, 75039, United States

  • NEO-811 Grand Rapids Site

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • NEO-811 Houston Site

    RECRUITING

    Houston, Texas, 77054, United States

  • NEO-811 Long Island Site

    RECRUITING

    Lake Success, New York, 11042, United States

  • NEO-811 South Carolina Site

    RECRUITING

    Myrtle Beach, South Carolina, 29572, United States

  • NEO-811 Virginia Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • NEO-811-101 NYC Site

    RECRUITING

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.